ArticlePharmacology, biochemistry, and behavior2018
Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period.
Article in Pharmacology, biochemistry, and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Salivary gland function and redox status in young adult male rats treated with the psychostimulant short-release methylphenidate.Odontology · 2026Article
- Chronic Co-administration of Methylphenidate and Fluoxetine Reduces Striatal NMDA Receptor Binding in Adolescent Rats.Neurochemical research · 2026Article
- Methylphenidate leads to disruptions in rest/wake patterns after discontinuation.Psychopharmacology · 2026Article
- Sex differences in the response to treatment of attention deficit hyperactivity disorder.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions.Neurochemical research · 2025Article
- Vaporized nicotine in utero results in reduced birthweight, increased locomotion, and decreased voluntary exercise, dependent on sex and diet in offspring.Psychopharmacology · 2024Article
- Chronic Methylphenidate Effects on Brain Gene Expression: An Exploratory Review.Psychology research and behavior management · 2024Review
- Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration.Addiction neuroscience · 2023Article
- Behavioral, Neurochemical and Developmental Effects of Chronic Oral Methylphenidate: A Review.Journal of personalized medicine · 2023Review
- Emotional and sensory dysregulation as a possible missing link in attention deficit hyperactivity disorder: A review.Frontiers in behavioral neuroscience · 2023Review
- Role of environmental enrichment on social interaction, anxiety, locomotion, and memory in Wistar rats under chronic methylphenidate intake.Frontiers in behavioral neuroscience · 2023Article
- Fluoxetine Potentiates Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum.Molecular neurobiology · 2021Article
- Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.Developmental psychobiology · 2020Article
- Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects.Behavioural brain research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic oral methylphenidate (MP) exposure in rats is associated with numerous developmental and behavioral consequences. The present study investigated the persistence of the effects of chronic oral MP exposure after abstinence from MP use. Male and female rats were exposed to daily orally self-administered water, low dose MP (LD), or high dose (HD) MP for 13 weeks, followed by a 4-week abstinence period. Fluid, food consumption and bodyweights were monitored and animals were tested for locomotor activity, anxiety- and depressive-like symptoms, learning and memory, and social behavior during both the treatment and abstinence phases of the experiment. During treatment, MP attenuated bodyweight regardless of sex, but increased food and fluid consumption in females and males by 20.7% and 30.1%, respectively. MP also increased locomotor activity in both males and females observed as increased distance travelled in an open field. (59.1% and 95.9%, respectively) and increased locomotor activity in the home cage over a 24-hour circadian cycle (45.5% and 63.0%). Additionally, MP exerted an anxiolytic effect observed as increased time spent in the open arms of an elevated plus maze (31.1% in HD males, 59.2% in HD females), and an increased latency to immobility in a forced swim test (330% in HD males, 418% in HD females). The effects of MP (bodyweight, consumption, locomotion, anxiolytic, and anti-depressive) were, almost without exception, eliminated during the abstinence period. MP had no impact on learning and memory performance as measured by a T-maze, or social behavior during treatment. These findings suggest that the behavioral consequences of chronic oral MP treatment in our preclinical model are reversible in rats following an abstinence period from use of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.